Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said after the close of the market Friday that it is acquiring Affymetrix for approximately $1.3 billion.

The firms said in a joint statement that the boards of directors of both firms have unanimously approved Thermo Fisher's offer to acquire Affymetrix for $14 per share, a 52 percent premium to Affy's closing price of $9.21 on Friday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.